About the Program
The Mood and Anxiety Disorders Program at Baylor College of Medicine is committed to caring for those with mood and anxiety disorders and to discovering new, innovative therapies for patients suffering from these conditions to improve the quality of life for these individuals and their families. The program pursues excellence in patient-oriented research, education, and community outreach with a spirit of beneficence, humility, and integrity.
Our Research
Our research program is dedicated to research on depression, bipolar disorder, anxiety, suicidality, and post-traumatic stress disorder (PTSD). Many of our current studies involve testing and developing novel treatments for these disorders. Other studies focus on better understanding their causes, progression, and course over time. If you or someone you know is struggling with one of these disorders and not responding well to current treatment, please consider participating in one of our clinical research trials.
Current Studies include:
- Depression
- Post Traumatic Stress Disorder
- Generalized Anxiety Disorder
- Other associated studies
The why, when, where, how, and so what of so-called rapidly acting antidepressants with Dr. Sanjay Mathew
Publications
Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B (2023): Ketamine versus ECT for non-psychotic treatment-resistant major depression. N Engl J Med 388 (25): 2315-2325.
Price RB, Wallace ML, Mathew SJ, Howland RH (2023): One-year outcomes following intravenous ketamine plus digital training among patients with treatment-resistant depression: a secondary analysis of a randomized clinical trial. JAMA Netw Open May 1; 6(5):e2312434.
Price RB, Spotts C, Panny B, Griffo A, Degutis M, Cruz N, Bell E, Do-Nguyen K, Wallace ML, Mathew SJ, Howland RH (2022): A novel, brief, full automated intervention to extend the antidepressant effect of a single ketamine infusion: a randomized clinical trial. Am J Psychiatry 179 (12): 959-968.
Sheth SA, Bijanki KR, Metzger B, Allawala A, Pirtle V, Adkinson JA, Myers J, Mathura RK, Oswalt D, Tsolaki E, Xiao J, Noecker A, Strutt AM, Cohn JF, McIntyre CC, Mathew SJ, Borton D, Goodman W, Pouratian N (2022): Deep brain stimulation for depression informed by intracranial recordings. Biol Psychiatry 92(3): 246-251.
Murphy N, Ramakrishnan N, Vo-Le B, Vo-Le B, Smith MA, Iqbal T, Swann AC, Mathew SJ,* Lijffijt M (2021). A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-D-aspartate receptor blockade in healthy veterans. Neuropsychopharmacology 46(4): 820-827.
Costi S, Morris LS, Kirkwood KA, Hoch M, Corniquel M, Vo-Le B, Iqbal T, Chadha N, Pizzagalli DA, Whitton A, Bevilacqua L, Jha MK, Ursu S, Swann AC, Collins KA, Salas R, Bagiella E, Parides MK, Stern ER, Iosifescu DV, Han MH, Mathew SJ, Murrough JW (2021): Impact of the KCNQ2/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression: results from a randomized controlled trial. Am J Psychiatry 178(5): 437-446.
Rivas-Grajales AM, Salas R, Robinson ME, Qi K, Murrough JW, Mathew SJ (2020). Habenula connectivity and intravenous ketamine in treatment-resistant depression. International Journal of Neuropsychopharmacology 24(5): 383-391.
Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, Goodman W, Szabo ST, Whitton AE, Gao K, Potter WZ (2020): A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nature Medicine 26(5): 760-768.
Murrough JW, Abdallah CB, Mathew SJ (2017): Targeting glutamate signaling in depression: progress and prospects. Nature Reviews Drug Discovery 16(7): 472-486.
Mathew SJ, Guerguieva R, Brandt C, Fava M, Sanacora G (2017). A randomized, double-blind, placebo-controlled, sequential parallel comparison design trial of adjunctive riluzole for treatment-resistant major depressive disorder. Neuropsychopharmacology 42(13): 2567-2574.
Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Juri RK, Iqbalk SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ (2014). Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in TRD. Depression Anxiety 31(4): 335-43.
Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CM, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site, randomized controlled trial. Am J Psychiatry, 170 (10), 1134-1142.
Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, Dyke JP, Medow MS, Natelson BH, Stewart JM, Mathew SJ (2012). Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR in Biomedicine, 25(9), 1073-1087.
Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry, 67 (2), 139-145.
Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins K, Murrough J, Charney DS, Mathew SJ (2009). Amino acid neurotransmitter concentrations in anterior cingulate and occipital cortex in symptomatic patients with major depression: relationship to treatment resistance. Biol Psychiatry, 65(9):792-800.
Mathew SJ, Price RB, Mao X, Smith EL, Coplan JD, Charney DS, Shungu DC (2008). Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry 63(9): 891-898.
Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM (2005). Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162.